These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 19139209)

  • 1. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
    Hinz B; Renner B; Cheremina O; Besz D; Zolk O; Brune K
    Ann Rheum Dis; 2009 Feb; 68(2):289-91. PubMed ID: 19139209
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lumiracoxib taken off the market in Australia. What does that mean for our patients? (interview by Dr. Judith Neumaier)].
    Brune K
    MMW Fortschr Med; 2007 Sep; 149(39):6. PubMed ID: 17987737
    [No Abstract]   [Full Text] [Related]  

  • 3. Lumiracoxib-induced cholestatic liver injury.
    Fok KC; Bell CJ; Read RB; Eckstein RP; Jones BE
    Intern Med J; 2013 Jun; 43(6):731-2. PubMed ID: 23745998
    [No Abstract]   [Full Text] [Related]  

  • 4. [Lumiracoxib--Prexigem].
    Duh D; Vandevijver A
    J Pharm Belg; 2007; 62(3):95-6. PubMed ID: 17955960
    [No Abstract]   [Full Text] [Related]  

  • 5. Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study.
    Capuano A; De Corato A; Treglia M; Tringali G; Dello Russo C; Navarra P
    Eur J Pharmacol; 2009 Mar; 605(1-3):57-62. PubMed ID: 19168053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of lumiracoxib in patients with analgesic intolerance.
    Celikel S; Isik SR; Karakaya G; Kalyoncu AF
    J Investig Allergol Clin Immunol; 2008; 18(4):318-9. PubMed ID: 18714545
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?
    Chitturi S; Farrell GC
    J Gastroenterol Hepatol; 2012 Jun; 27(6):993-4. PubMed ID: 22621454
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe acute liver injury associated with lumiracoxib.
    Pillans PI; Ghiculescu RA; Lampe G; Wilson R; Wong R; Macdonald GA
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1102-5. PubMed ID: 22142375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology.
    Hinz B; Brune K
    Trends Pharmacol Sci; 2008 Aug; 29(8):391-7. PubMed ID: 18606461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats.
    Ortiz MI; Castañeda-Hernández G
    Eur J Pain; 2008 Feb; 12(2):233-41. PubMed ID: 17606391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro metabolic activation of lumiracoxib in rat and human liver preparations.
    Li Y; Slatter JG; Zhang Z; Li Y; Doss GA; Braun MP; Stearns RA; Dean DC; Baillie TA; Tang W
    Drug Metab Dispos; 2008 Feb; 36(2):469-73. PubMed ID: 17998295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.
    Vélez de Mendizábal N; Vásquez-Bahena D; Jiménez-Andrade JM; Ortiz MI; Castañeda-Hernández G; Trocóniz IF
    AAPS J; 2012 Dec; 14(4):904-14. PubMed ID: 22968496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
    Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects.
    Scott G; Yih L; Yeh CM; Milosavljev S; Laurent A; Rordorf C
    J Clin Pharmacol; 2004 Feb; 44(2):193-9. PubMed ID: 14747429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of aceclofenac and nabumetone in osteoarthritis.
    Paul S; Das N; Ghosh S
    JNMA J Nepal Med Assoc; 2009; 48(174):121-5. PubMed ID: 20387351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
    Hawkey CJ; Ell C; Simon B; Albert J; Keuchel M; McAlindon M; Fortun P; Schumann S; Bolten W; Shonde A; Hugot JL; Yu V; Arulmani U; Krammer G; Rebuli R; Toth E
    Clin Gastroenterol Hepatol; 2008 May; 6(5):536-44. PubMed ID: 18242145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.